Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

Phase 2Nu-3Positive

AI Analysis

Summary

Lakewood-Amedex Biotherapeutics announced the first patient dosed in a Phase 2a clinical trial of Nu-3 for infected diabetic foot ulcers, with topline data expected in Q1 2027. The milestone represents advancement of the company's proprietary Bisphosphocin antimicrobial platform.

Clinical Trial Data

Phase

Outcome Details

First patient dosed in Phase 2a clinical trial

Importance:5/10

Sentiment:

0.60

Clinical TrialPhase 2AntimicrobialDiabetic Foot UlcersBisphosphocin Platform

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on September 24, 2026 12:02 PM

Read Original